Loading patent…
AssigneeNovartis Nutrition AG
InventorsSharon Marie Gohman, Lester David Michels, Norman Alan Greenberg, David Curtis Egberg
Estimating the term…
A therapeutically effective amount of L-arginine, or a physiologically acceptable salt thereof, is orally administered, preferably as a food supplement in combination with a meal approved by the American Diabetes Association Inc. ("ADA"), to a person having Type II diabetes mellitus but who is not on either insulin or other medication for glycemic control. When 3 g to 15 g of L-arginine is ingested concurrently with a meal, or immediately prior to eating a meal, the L-arginine decreases the concentration of insulin generated, compared to that generated after the same meal without the L-arginine; at the same time, concentration of glucose in the person's blood is decreased, indicating that available insulin sensitizes cells so as to nearly mimic the effectiveness of normal cells in a non-diabetic person; from 3 g to 15 g of orally ingested L-arginine, by itself, produces no measurable increase in insulin secretion in a diabetic.
A meal for a person having non-insulin-dependent diabetes mellitus comprising a meal approved by the American Diabetes Association Inc. ("ADA") or equivalent, said meal having less than about 1000 Kcal in combination with a food supplement comprising a non-nutritional but therapeutically effective amount of L-arginine in the range from 3 g to 15 g, or a physiologically acceptable salt thereof, blended into a an essentially sugar-free palatable food component or carrier having a total caloric intake of less than 150 Kcal.
A food supplement comprising a non-nutritional but therapeutically effective amount of L-arginine in the range from 3 g to 15 g, or a physiologically acceptable salt thereof, blended into an essentially sugar-free palatable food component or carrier having a total caloric intake of less than 150 Kcal, whereby said L-arginine is readily assimilable by a person having non-insulin-dependent diabetes mellitus.
A method of treating a Type II diabetic comprising, enterally administering to said diabetic an approved meal in combination with a therapeutically effective amount of L-arginine or a physiologically acceptable salt thereof, as an essentially non-nutritional sugar-free food supplement;
A method of treating a person having non-insulin-dependent diabetes mellitus comprising, orally administering to said person a therapeutically effective amount of L-arginine or a physiologically acceptable salt thereof in combination with an approved meal;
Dependencies are inferred from the claim text.